MarketInOut Stock Screener Log In | Sign Up
 

Evolus Inc

NASDAQ • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 09/21/2026 16:00
Evolus Inc stock price and volume chart

Company Profile

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization519.16 mln
Float65.23 mln
Earnings Date11/10/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-2.69
Likely reliable

1-Year Forecast

15.00
Transformational upside

Relative Strength

8 / 100
Severely lagging

Pre-Tax Margin

-11%
Loss-making

ROE

123
Extraordinary

Business Description

Evolus is a US-based aesthetics company that sells directly to consumers in the United States, Canada, Europe, and Australia. Its main product, Jeuveau, is an injectable treatment that temporarily reduces the appearance of frown lines between the eyebrows. The company also offers Evolysse, a range of injectable fillers designed to restore volume and smooth the appearance of the face, lips, and eyes. Founded in 2012, Evolus operates out of Newport Beach, California.

Key Fundamentals

EPS-0.53
ROE123
RPS4.86
ROIC-17.74
ROA-15.03
Interest Cover-1.43
EBITDA, mln-8.37
EV / EBITDA-84.35
EV / EBIT-40.44
Revenue, mln316
EV / Revenue2.23

Quote Details

Last 7.99
Change 0.13 (1.65%)
Open 7.93
Volume 420,561
Turnover 3,360,282
Average Volume 973,821

Financial Ratios

Pre-Tax Profit Margin-11
Current Ratio1.70
Price / Sales1.83

Financial Strength

Altman Z-Score-1.2
Piotroski F-Score 3 / 9
Beneish M-Score-2.69
1-Year Target Price15.00
Short Ratio4.61
Short % of Float8.23

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.76% 60 / 100   
1 Month -4.31% 30 / 100   
2 Months 18.72% 88 / 100   
6 Months 72.2% 94 / 100   
1 Year 24.45% 79 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us